# Marchex Inc: financial statements, quarterly MCHX · Nasdaq · CIK 1224133 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mchx.md) · [Financials](/companies/mchx/financials.md) · [Filings](/companies/mchx/filings.md) · [Insiders](/companies/mchx/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mchx/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.8](/filings/0000950170-24-120081.md) | [12.4 d](/filings/0000950170-25-039513.md) | [11.6](/filings/0000950170-25-071406.md) | [12.1](/filings/0001224133-25-000008.md) | [12.6](/filings/0001193125-25-282989.md) | [11.9 d](/filings/0001193125-26-125205.md) | [11.4](/filings/0001193125-26-224062.md) | [11.7](/filings/0001193125-26-349234.md) | [11.5](/filings/0001193125-25-282989.md) | [10.8 d](/filings/0001193125-26-125205.md) | [10.6](/filings/0001193125-26-224062.md) | [11.0](/filings/0001193125-26-349234.md) | | Cost of revenue | $m | [5.1](/filings/0000950170-24-120081.md) | [4.7 d](/filings/0000950170-25-039513.md) | [4.4](/filings/0000950170-25-071406.md) | [4.2](/filings/0001224133-25-000008.md) | [4.2](/filings/0001193125-25-282989.md) | [4.4 d](/filings/0001193125-26-125205.md) | [4.2](/filings/0001193125-26-224062.md) | [4.1](/filings/0001193125-26-349234.md) | [4.2](/filings/0001193125-25-282989.md) | [4.2 d](/filings/0001193125-26-125205.md) | [4.2](/filings/0001193125-26-224062.md) | [4.4](/filings/0001193125-26-349234.md) | | Research and development | $m | [3.9](/filings/0000950170-24-120081.md) | [3.2 d](/filings/0000950170-25-039513.md) | [3.2](/filings/0000950170-25-071406.md) | [3.2](/filings/0001224133-25-000008.md) | [3.1](/filings/0001193125-25-282989.md) | [2.8 d](/filings/0001193125-26-125205.md) | [2.7](/filings/0001193125-26-224062.md) | [2.5](/filings/0001193125-26-349234.md) | [2.4](/filings/0001193125-25-282989.md) | [2.2 d](/filings/0001193125-26-125205.md) | [2.4](/filings/0001193125-26-224062.md) | [2.0](/filings/0001193125-26-349234.md) | | Operating income | $m | [(1.3)](/filings/0000950170-24-120081.md) | [(1.1) d](/filings/0000950170-25-039513.md) | [(1.3)](/filings/0000950170-25-071406.md) | [(0.7)](/filings/0001224133-25-000008.md) | [(0.8)](/filings/0001193125-25-282989.md) | [(1.6) d](/filings/0001193125-26-125205.md) | [(1.9)](/filings/0001193125-26-224062.md) | [(0.5)](/filings/0001193125-26-349234.md) | [(0.9)](/filings/0001193125-25-282989.md) | [(2.4) d](/filings/0001193125-26-125205.md) | [(1.4)](/filings/0001193125-26-224062.md) | [(0.3)](/filings/0001193125-26-349234.md) | | Income tax | $m | [0.0](/filings/0000950170-24-120081.md) | [0.0 d](/filings/0000950170-25-039513.md) | [0.1](/filings/0000950170-25-071406.md) | [0.0](/filings/0001224133-25-000008.md) | [0.0](/filings/0001193125-25-282989.md) | [0.3 d](/filings/0001193125-26-125205.md) | [0.1](/filings/0001193125-26-224062.md) | [0.0](/filings/0001193125-26-349234.md) | [0.0](/filings/0001193125-25-282989.md) | [(0.1) d](/filings/0001193125-26-125205.md) | [0.2](/filings/0001193125-26-224062.md) | [0.1](/filings/0001193125-26-349234.md) | | Net income | $m | [(1.5)](/filings/0000950170-24-120081.md) | [(1.1) d](/filings/0000950170-25-039513.md) | [(1.5)](/filings/0001193125-25-282989.md) | [(0.8)](/filings/0001193125-25-282989.md) | [(0.8)](/filings/0001193125-25-282989.md) | [(1.9) d](/filings/0001193125-26-125205.md) | [(2.0)](/filings/0001193125-26-349234.md) | [0.1](/filings/0001193125-26-349234.md) | [(1.0)](/filings/0001193125-25-282989.md) | [(2.3) d](/filings/0001193125-26-125205.md) | [(1.7)](/filings/0001193125-26-349234.md) | [(0.4)](/filings/0001193125-26-349234.md) | | Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-120081.md) | not reported | [(0.03)](/filings/0000950170-25-071406.md) | [(0.02)](/filings/0001224133-25-000008.md) | [(0.02)](/filings/0001193125-25-282989.md) | not reported | [(0.05)](/filings/0001193125-26-224062.md) | [0.00](/filings/0001193125-26-349234.md) | [(0.02)](/filings/0001193125-25-282989.md) | not reported | [(0.04)](/filings/0001193125-26-224062.md) | [(0.01)](/filings/0001193125-26-349234.md) | | Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-120081.md) | not reported | [(0.03)](/filings/0000950170-25-071406.md) | [(0.02)](/filings/0001224133-25-000008.md) | [(0.02)](/filings/0001193125-25-282989.md) | not reported | [(0.05)](/filings/0001193125-26-224062.md) | [0.00](/filings/0001193125-26-349234.md) | [(0.02)](/filings/0001193125-25-282989.md) | not reported | [(0.04)](/filings/0001193125-26-224062.md) | [(0.01)](/filings/0001193125-26-349234.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [13.7](/filings/0000950170-23-062920.md) | [14.6](/filings/0000950170-25-039513.md) | [12.0](/filings/0000950170-24-059658.md) | [12.0](/filings/0000950170-24-096238.md) | [12.1](/filings/0000950170-24-120081.md) | [12.8](/filings/0001193125-26-125205.md) | [10.0](/filings/0000950170-25-071406.md) | [10.5](/filings/0001224133-25-000008.md) | [10.3](/filings/0001193125-25-282989.md) | [9.9](/filings/0001193125-26-349234.md) | [9.0](/filings/0001193125-26-224062.md) | [8.2](/filings/0001193125-26-349234.md) | | Current assets | $m | [24.0](/filings/0000950170-23-062920.md) | [23.8](/filings/0000950170-25-039513.md) | [22.5](/filings/0000950170-24-059658.md) | [22.5](/filings/0000950170-24-096238.md) | [21.8](/filings/0000950170-24-120081.md) | [22.3](/filings/0001193125-26-125205.md) | [19.9](/filings/0000950170-25-071406.md) | [21.1](/filings/0001224133-25-000008.md) | [20.4](/filings/0001193125-25-282989.md) | [19.0](/filings/0001193125-26-349234.md) | [18.1](/filings/0001193125-26-224062.md) | [17.4](/filings/0001193125-26-349234.md) | | Total assets | $m | [49.1](/filings/0000950170-23-062920.md) | [47.5](/filings/0000950170-25-039513.md) | [45.6](/filings/0000950170-24-059658.md) | [45.5](/filings/0000950170-24-096238.md) | [44.1](/filings/0000950170-24-120081.md) | [43.2](/filings/0001193125-26-125205.md) | [40.6](/filings/0000950170-25-071406.md) | [42.0](/filings/0001224133-25-000008.md) | [41.1](/filings/0001193125-25-282989.md) | [39.7](/filings/0001193125-26-349234.md) | [38.5](/filings/0001193125-26-224062.md) | [37.6](/filings/0001193125-26-349234.md) | | Current liabilities | $m | [9.8](/filings/0000950170-23-062920.md) | [9.7](/filings/0000950170-25-039513.md) | [9.0](/filings/0000950170-24-059658.md) | [9.5](/filings/0000950170-24-096238.md) | [8.7](/filings/0000950170-24-120081.md) | [9.3](/filings/0001193125-26-125205.md) | [8.0](/filings/0000950170-25-071406.md) | [8.7](/filings/0001224133-25-000008.md) | [8.1](/filings/0001193125-25-282989.md) | [8.1](/filings/0001193125-26-349234.md) | [8.2](/filings/0001193125-26-224062.md) | [7.6](/filings/0001193125-26-349234.md) | | Total liabilities | $m | [11.8](/filings/0000950170-23-062920.md) | [11.6](/filings/0000950170-25-039513.md) | [10.7](/filings/0000950170-24-059658.md) | [11.0](/filings/0000950170-24-096238.md) | [10.0](/filings/0000950170-24-120081.md) | [10.6](/filings/0001193125-26-125205.md) | [9.3](/filings/0000950170-25-071406.md) | [9.9](/filings/0001224133-25-000008.md) | [9.2](/filings/0001193125-25-282989.md) | [9.6](/filings/0001193125-26-349234.md) | [9.7](/filings/0001193125-26-224062.md) | [8.6](/filings/0001193125-26-349234.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | [0.8](/filings/0000950170-24-038807.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [37.3](/filings/0000950170-24-120081.md) | [35.9](/filings/0001193125-26-125205.md) | [34.9](/filings/0001193125-25-282989.md) | [34.5](/filings/0001193125-25-282989.md) | [34.1](/filings/0001193125-25-282989.md) | [32.6](/filings/0001193125-26-349234.md) | [31.4](/filings/0001193125-26-349234.md) | [32.0](/filings/0001193125-26-349234.md) | [31.9](/filings/0001193125-25-282989.md) | [30.1](/filings/0001193125-26-349234.md) | [28.9](/filings/0001193125-26-349234.md) | [29.0](/filings/0001193125-26-349234.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Current portion of debt: not reported - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(378) d](/filings/0000950170-24-120081.md) | [1,754 d](/filings/0000950170-25-039513.md) | [(2,478)](/filings/0000950170-25-071406.md) | [117 d](/filings/0001224133-25-000008.md) | [382 d](/filings/0001193125-25-282989.md) | [875 d](/filings/0001193125-26-125205.md) | [(2,622)](/filings/0001193125-26-224062.md) | [803 d](/filings/0001193125-26-349234.md) | [290 d](/filings/0001193125-25-282989.md) | [121 d](/filings/0001193125-26-125205.md) | [(514)](/filings/0001193125-26-224062.md) | [(649) d](/filings/0001193125-26-349234.md) | | Capital expenditure | $k | [2.0 d](/filings/0000950170-24-120081.md) | [853 d](/filings/0000950170-25-039513.md) | [4.0](/filings/0000950170-25-071406.md) | [77.0 d](/filings/0001224133-25-000008.md) | [183 d](/filings/0001193125-25-282989.md) | [118 d](/filings/0001193125-26-125205.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-282989.md) | [5.0 d](/filings/0001193125-26-125205.md) | not reported | not reported | | Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: not reported - Share repurchases: not reported Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.